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Abstract
Background: The definition of transcriptional networks through measurements of changes in gene expression profiles and
mapping of transcription factor binding sites is limited by the moderate overlap between binding and gene expression
changes and the inability to directly measure global nuclear transcription (coined ‘‘transactome’’).
Methodology/Principal Findings: We developed a method to measure nascent nuclear gene transcription with an Array-
based Nuclear Run-On (ANRO) assay using commercial microarray platforms. This strategy provides the missing component,
the transactome, to fully map transcriptional networks. ANRO measurements in an inducible c-Myc expressing human P493-
6 B cell model reveals time-dependent waves of transcription, with a transactome early after c-Myc induction that does not
persist at a late, steady-state phase, when genes that are regulated by c-Myc and E2F predominate. Gene set matrix analysis
further uncovers functionally related groups of genes putatively regulated by waves of transcription factor motifs following
Myc induction, starting with AP1 and CREB that are followed by EGR1, NFkB and STAT, and ending with E2F, Myc and ARNT/
HIF motifs.
Conclusions/Significance: By coupling ANRO with previous global mapping of c-Myc binding sites by chromatin
immunoprecipitation (ChIP) in P493-6 cells, we define a set of transcriptionally regulated direct c-Myc target genes and pave
the way for the use of ANRO to comprehensively map any transcriptional network.
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Introduction
Deregulated expression of the MYC oncogene, which encodes
c-Myc, occurs in about 30% of human cancers, including a
substantial fraction of many commonly occurring cancers such as
colon, prostate, liver and breast carcinomas [1]. c-Myc (herein
termed Myc) is a helix-loop-helix leucine zipper transcription
factor that heterodimerizes with a partner protein Max, which is a
hub in the network of protein-protein interactions with MAD
proteins[2,3]. Upon heterodimerization, Myc–Max binds specific
DNA sites termed E-boxes to activate or repress transcription as
well as modulate chromatin structure. Myc competes with Mad
proteins via mass action and hetero-dimerizes with MAX. Hence,
upon serum stimulation of starved cells, the induction of MYC
results in a rapid rise in level of Myc that dimerizes with Max and
transregulate target genes. With limiting nutrients or high cellular
density, Myc levels in normal cells decrease, resulting in the
cessation of cell proliferation. By contrast, cancer cells with
deregulated MYC enforce a transcriptional growth response that is
independent of external cues.
The composition of the Myc–Max target gene network is likely
to be cell-type specific; however, a core set of MYC target genes
appears to exist [4]. Genes involved in ribosomal biogenesis have
been linked genetically in Drosophila to regulation by dMyc and
recently shown by genomic analysis to comprise a conserved set of
Myc target genes [5]. Myc also directly activates genes involved in
nucleolar and ribosomal proteins as well as those regulated by
RNA polymerases I and III, including ribosomal RNA genes [2].
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cycle and energy metabolism later in evolution through affecting
the expression of genes involved in glucose metabolism and
mitochondrial biogenesis. In higher organisms, Myc has been
implicated in the regulation of mRNAs and microRNAs involved
in angiogenesis[6]. Many of the conclusions reached to date
regarding the Myc target gene networks rely on gene expression
changes coupled with Myc binding to target genes as determined
by chromatin immunoprecipitation (ChIP)[7,8].
Numerous ChIP studies have been performed with Myc, and
our own study revealed many more binding sites (,3000 genes)
than there are corresponding changes in mRNA levels (,700) of
genes that Myc bound [7,9,10]. This observation has been
corroborated by Kim et al., who further found in mouse
embryonic stem cells that gene expression changes best correlate
with multiple transcription factor binding, such that binding of a
single transcription factor to any gene loci is infrequently
associated with changes at the mRNA level[9]. Hence, the
identification of direct target genes for any transcription factor
performed to date is limited by assuming that transcription factor
binding to target genes results in their altered transcriptional rates.
The fact that Myc could also regulate microRNAs suggests that
Myc could influence RNA stability as well as translation through
its regulation of miRNAs [2,3]
,[11]. In this regard, it is critical that
a tractable approach is developed for the measurement of global
changes in nuclear transcription so that regulation of mRNAs at
the transcriptional level (the transactome) could be distinguished
from post-transcriptional regulation.
Here, we report the development and implementation of an
Array-based Nuclear Run-On (ANRO) assay using commercial
microarray platforms to further define direct Myc target genes in
the P493-6 model of human Burkitt’s lymphoma. The human P-
493 B cell line has been engineered with an Epstein-Barr Virus
(EBV) genome together with a tetracycline-repressible human
MYC gene, such that tetracycline-treated resting cells could be
recruited into proliferation by the removal of tetracycline, which
induces Myc protein expression within three hours[12,13]. This
induction is followed by a coordinated entry of P493-6 cells into
the cell cycle with subsequent cell division[14]. Using this system,
we performed ANRO at different time points after the induction
of Myc and found waves of transcriptional changes (transactome)
followed by altered total mRNA levels (transcriptome). Through
Gene Set Matrix Analysis (GSMA), we found specific transcription
factor motifs enriched in promoters of the different waves of genes
following Myc induction. These dynamic transcriptional changes,
which heretofore had not been accessible at a global scale, reveal
early transcriptional changes that are silenced at steady state when
Myc-Max and E2F binding motifs are abundantly found in
promoters of transcribed genes. This system is ideal for the
identification of early versus delayed early responses to Myc at the
transcriptional level as well as post-transcriptional level. Together
with genomic binding data, ANRO will provide the heretofore
missing transactome for the comprehensive mapping of any
transcriptional network.
Results
Determination of the Transactome with Array-based
Nuclear Run-On Assay
Design of a global nuclear run-on assay. Based upon our
previous experience with a spotted filter-array-based nuclear run-on
(NRO) using radiolabeled UTP[15,16], our initial goal (Figure 1a)
was to substitute a non-radioactive labeled nucleotide (biotin-UTP)
during the metabolic labeling of primary nuclear run-on RNA in
order to select for newly transcribed (nascent) RNA only. Nascent
RNA labeled inthismannercouldbecaptured on streptavidinbeads
and first strand cDNA generated while the RNA remained
immobilized on beads [17]. We generated first strand cDNA with
bead-immobilized nascent RNAs using random primers coupled
withaT7promotersequence,releasedfirststrandcDNAfrombeads
byRNaseHtreatment,followedbysecondstrandcDNAsynthesisin
solution using random primers only. The NRO cRNA was
subsequently generated from column-purified NRO cDNA using
T7 polymerase and labeled with biotin-UTP.Purified, labeled NRO
cRNA can be then hybridized to most commercial microarray
platforms (Illumina, Affymetrix, and Agilent were successfully
tested).
We used two biological systems for the design of the ANRO
protocol. In one system we used phorbol ester activated Jurkat
T cells to determine the genomic responses as we described
previously[15,16]. The other system is the inducible MYC human
B lymphoma model cell line P493-6 described above.
Assay optimization. We found that ribosomal RNA
depletion (ribominus) of NRO RNA resulted in blunted signals
for genes whose expression levels were clearly altered. The overall
loss of gene information without any major commensurate gene
enrichment did not appear to warrant the inclusion of ribosomal
RNA removal in our protocols.
We determined the best concentration of T7 random hexamer
(T7N6) in order to ensure complete NRO first strand cDNA
synthesis. Figure 1b shows an example of optimization results
amongst replicate samples demonstrating that further increases in
primer and hybridization concentration combinations did not
increase overall signal intensities for a panel of previously
identified genes regulated by PMA and ionomycin treatment of
Jurkat T cells [18]. This observation indicates that we have
optimized the conditions and that the primer concentration for
NRO is not a limiting factor with the Illumina microarray. We
also found that the chronological order of binding of biotin-labeled
NRO RNA to streptavidin beads was vital for high efficiency. For
example, first strand cDNA synthesis in solution followed by
binding to beads was, surprisingly, much less effective than pre-
binding of NRO RNA to beads followed by solid-phase-based
synthesis. Similarly binding times, temperature and buffer
conditions were explored thoroughly and the detail protocol is
provided in the Supplementary section. It was empirically
determined that the RNAse H step for degrading template RNA
following first strand cDNA synthesis was indeed effective for
releasing the 1
st strand cDNA product from the streptavidin beads,
since the fully synthesized double stranded cDNA product
remained quantitatively in solution following bead centrifugation
and removal.
Assay reproducibility and transcript length. With the
optimized conditions, we sought to determine the reproducibility
of the techniques involved and to characterize the transcripts
produced by these methods. Figure 2a shows the increase in
transcription of CD69, one of the key genes induced by T cell
activation, and that NRO Illumina arrays faithfully reproduced
the proportional enrichment of CD69 primary mRNA as
measured by quantitative RT-PCR in each sample (Figure 2b).
In addition, we have validated a number of other genes that were
detected by ANRO (Supplemental Table S1)
A major concern with the use of conventional microarrays
combined with NRO is that the probe sequences on commercial
platforms are biased toward the 39 end of genes, while NRO
transcripts could be biased to the 59 end and therefore remain
undetected if full length transcripts were not generated with the
NRO procedure. Hence, we tested CD69, which is one of the
Genome-Wide Nuclear Run-On
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Jurkat T cells in both the NRO and total RNA [18].
A series of RT-PCR primers were designed to span exon-intron
junctions across CD69 (Figures 2c, d). The results showed that
in each case, a large and dramatic up-regulation of CD69 was
detected even with very large amplicon sizes (1400 nt) in both
synthesized cDNA and amplified cRNA. Additional characteriza-
tion of NRO amplified transcripts using Affymetrix Exon arrays
demonstrated that ANRO was indeed capable of detecting very
long transcripts reproducibly (Supplemental Figure S1). This
observation is compatible with the ability of the single Illumina
microarray probe at the CD69 39UTR (Figure 2d) to detect NRO
cRNAs. Furthermore, we found by substituting T7-Oligo dT
primers for T7N6 in the first strand synthesis in the ANRO process
that about 20% of the biotinylated NRO material was already
polyadenylated (data not shown), indicating rapid processing of
primary transcripts to mature mRNAs.
Cross platform comparisons. To further establish the
applicability of ANRO on different commercial microarray plat-
forms, we calculated statistically significant regulated gene expre-
ssion determined from a parallel series of experiments using both
the Affymetrix exon array and Illumina BeadArrays. Changes in
gene expression of a common pool of genes (,7800) were
determined for tetracycline-treated (tet) and untreated (MYC over-
expression) human P493-6 B cells for NRO and total RNA using
both microarray platforms. The results (Figure 3a) demonstrate
excellent comparability between platforms (PCC=0.82), treat-
ments (PCC=0.88), and methods (PCC=0.83).
Pathway analysis of the combined Affymetrix and Illumina
datasets demonstrates a high degree of consistency between
microarray platforms and between NRO and total RNA at the
geneset level (Figure 3b). This consistency is maintained on a
gene-by-gene basis as illustrated for interferon response genes up-
regulated by Myc over-expression (Figure 3c).
Definition of the Myc target gene network using ANRO
The availability of ANRO permits the study of transcriptional
responses to Myc activation as a function of time. First, we sought
to determine transcriptional differences between P493-6 cells
proliferating with high MYC expression and P493-6 cells that have
been treated with tetracycline for 48 hr when these cells do not
proliferate and have very low MYC expression. Table 1 shows
Figure 1. Array- based Nuclear Run-on (ANRO) development and optimization. (a) schematic for optimized ANRO protocol. (b) heat map
of relative gene expression intensities for a panel of test genes activated by PMA+ionomycin induction of human Jurkat T cells. Increasing amounts of
T7 random primer used in the first strand cDNA synthesis of Nuclear Run-on RNA accompanied by increasing amounts of the resulting cRNA
generated and applied to Illumina microarrays show no increase in signal.
doi:10.1371/journal.pone.0009691.g001
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expression in the P493-6 B cell system, including MYC gene itself.
Genes highly up-regulated as measured in the total RNA
preparations were similarly up-regulated in the NRO RNA and
overlapped with many known MYC target genes as shown
7.M y c
target genes, such as NME1 and Myc induced nuclear antigen
(MINA) are prominently represented in this group. The study also
revealed that many genes involved in nucleotide metabolism suchas
ACLY, AK3, AK5, APRT, ATP5B, ATP5D, ATP5I, ATP5O, GART,
IMPDH2, NME1, NME2, PAICS, PFAS, and PPAT are among
mRNAs significantly increased both at the steady state level and at
the nuclear run-on level with MYC induction, indicating that they
are all transcriptionally up-regulated. Ontology analysis of genes
that were transcriptionally up-regulated using the EASE algorithm
[19] indicates that Myc-responsive nucleotide metabolic genes are
highly statistically over-represented at p,10
27. These observations
are compatible with our identification of nucleotide metabolic genes
as direct Myc target genes [20].
After having established NRO sample reproducibility and
demonstrated comparability between transcription measured at
either the nuclear or whole cell level in the MYC model system after
48 hr, we next tested the ANRO method across a time course of
MYC overexpression and compared the results with conventional
microarray using total RNA. P493-6 cells were grown in the
continuous presence of tetracycline (MYC off), briefly washed in
PBS, and then incubated without tetracycline. Sequential parallel
samples were processed at 15 min, 30 min, 1 hr, 3 hr, and 6 hr for
totalRNAorNRORNAisolationand labeling.Figure4illustrates
this time course for all calculated changes in gene expression as
measured in NRO and total RNA. This study illustrates a very tight
concordance between both methods with a significant difference
that NRO appears to anticipate changes in gene expression at time
points earlier than they appear in total RNA, consistent with altered
transcriptional rates followed by changes in total RNA.
As seen in Figure 5 (see Supplemental Table S2 and S3 for
accompanying gene lists), Myc activation is followed by waves of gene
expression changes that accompanied transcriptional activation of
clusters of genes. These experiments provide the first direct
observation of global transcriptional changes as a function of time
following Myc activation. We identified clusters of genes that respond
rapidly to Myc (within 1 hr), those that have a delayed early response
(after 3–6 hr), and those occurring late or at steady-state. These time-
dependent waves of transcription following Myc activation are likely
to represent direct and indirect Myc effects, whose definition is
beyond the scope of the current study. Gene ontology analysis reveals
that early Myc-mediated transcription involves early response genes
regulating MAPK signaling, RNA metabolism and transcription
factors,suggestingaprogramthatpreparesthecellsforSphase entry.
The delayed early genes are enriched with those involved in
ribosomal biogenesis, nucleotide metabolism and energy (pyruvate)
metabolism, indicating the subsequent preparation of cells to increase
biosynthetic capabilities for DNA replication. Finally, the late or
steady-state transcription involves genes that regulate energy
(oxidative phosphorylation), cell cycle or DNA replication.
Examination of transcription factor binding motifs by GSMA
reveals a stepwise putative involvement of distinct transcription
factors following the initial activation of Myc expression in the
P493-6 human B cells (Figure 6; see Supplemental Table S4 for
accompanying transcription factor motifs lists). Intriguingly, early
transcription involves factors that also play a role in immediate
Figure 2. Array- based Nuclear Run-on (ANRO) characterization. (a, b) Transcriptional regulation of CD69 in NRO RNA following Jurkat T Cell
activation. (a) Illumina microarray - CD69 average signal intensity for 4 independent experiments. (b) CD 69 Real time PCR validation for the same
experiments (fold changes were normalized by GAPDH controls). (c, d) RT-PCR estimates of varying amplicon size and complexity for CD69 gene
transcription in PMA + I activated Jurkat T cell NRO RNA. (c) Fold changes for CD69 in NRO RNA were tested using either first strand cDNA or the final
amplified cRNA product (as indicated). Multiple amplicons of GAPDH were similarly tested as an uninduced control. (d) CD69 amplicon primer design
spans exon-intron genomic sequences of sizes as indicated (primer sequences are reported in Materials and Methods). Note the location of the
Illumina microarray probe located at the 39UTR.
doi:10.1371/journal.pone.0009691.g002
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subsequent phases, a wide variety of motifs emerged with Myc/
Max, STAT, E2F appearing in the promoters of many genes
transcribed at 3–6 hours. Thereafter, at the late steady-state phase,
most genes transcribed at the earlier hours are repressed and
accompanied by the appearances of genes that are induced
putatively by transcription factors Myc/Max, E2F, HIF/ARNT
and YY1. These late transcription factors have been implicated in
the regulation of nucleotide metabolism and DNA replication. In
this regard, earlier waves of transcriptional events would be missed
at steady state without ANRO. Many of the earlier phase genes
that are later down-regulated are involved in B cell development,
indicating that sustained Myc activation leads to the silencing of
these differentiation-related genes in favor of those that drive cells
into cycle with a sustained proliferative program.
Global Map of Direct Transcriptional Targets of Myc in
Human P493-6 B cells
We superimposed our global Myc binding data from our
earlier ChIP-PET studies
7 with the ANRO results and derived
a minimal set of direct transcriptional targets of Myc in the
P493-6 system (Table 1 and Supplemental Table S5). Gene set
enrichment analysis (GSEA; http://www.broad.mit.edu/gsea/
index.jsp) of over 200 direct Myc up-regulated target genes
in P493-6 cells reveals a significant overlap with embryonic
(p=3.2e
216) or neural (p=9.4e
219) stem cell gene sets. This obser-
vation is consistent with the suppression of B cell differentiation
genes in the time course ANRO study discussed above. Moreover
with GSEA, the set of 340 direct down-regulated target genes most
striking overlap with the receptor CD40-upregulated gene set
(p=2.4e
218, BASSO GERMINAL CENTER_CD40_UP), which
are involved in germinal center development and generation of
memory B cells. It is notable that the ChIP-PET studies were
incomplete since only 60 percent sequencing saturation of the
ChIP-PET library was achieved
7. Hence, it is critical to note that
this is only a minimal set, pending further ChIP-chip studies to re-
map Myc binding sites in the P493-6 system. Nonetheless, the
ANRO approach we describe here is generally applicable to all
transcription factors using commercially available arrays coupled
with our protocol.
Figure 3. Array- based Nuclear Run-on (ANRO) shows consistent results between Affymetrix exon arrays and Illumina BeadChips.
(a) Pearson’s Correlation Matrix of changes in gene expression (log ratios) between tet treated (T) and untreated (UT) P493-6 human B cells following
48 hr induction for a common pool of approximately 7800 genes as measured on both Illumina BeadArrays and Affymetrix Exon microarray
platforms. (b) heat map illustrating a selection of the highest scoring pathways using Gene Set Matrix Analysis (GSMA) on the logratios from (a). (c)
Pathway breakout from b on a gene by gene basis for the Inteferon a, b Response Genes. Log ratios sorted descending on the NRO as measured on
the Illumina platform ((ILL T-UT NRO).
doi:10.1371/journal.pone.0009691.g003
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We report here the global measurement of transcription by
adapting the nuclear run-on assay to commercial microarrays.
Our approach contrasts with a recently published nuclear run-on
assay using direct sequencing of cDNA libraries from immunoaf-
finity captured Br-UTP labeled nascent RNAs without the
accompanying analysis of total RNA levels [21]. ANRO, which
relies on the 10
215 M Kd of streptavidin-biotin binding, also
contrasts with the use of thiouridine-labeled nascent RNAs which
were captured on lower binding affinity to organomercurial matrix
[22]. In addition, the use of commercially available microarrays as
describe in our study makes our method technically and
economically more accessible to most researchers. In fact, we
found that both Affymetrix and Illumina microarrays were
equivalent for ANRO, making ANRO more widely accessible.
Specifically, we developed, optimized and applied this approach,
termed Array-based Nuclear Run-On (ANRO), to map the Myc
transcriptional network in a human B cell lymphoma model
bearing an inducible Myc construct. It is notable, however, that
ANRO measures transcription with isolated nuclei rather than
intact cells. Hence, a more physiological reflection of transcription
will require future technical advances that enables incorporation of
biotinylated UTP in intact cells. Notwithstanding this caveat, the
inducibility of Myc enables a time-course study that provides an
unprecedented view of global transcriptional responses in isolated
nuclei to Myc induction. In particular, we observe waves of
transcriptional events following Myc induction that seems to
prepare cells for entry into subsequent phases of the cell cycle.
Importantly, the initial synchrony of the cells after Myc activation
permits the detection of early transactivation events involved in the
regulation of RNA metabolism of genes and later events involving
ribosomal biogenesis, nucleotide and energy metabolism. Remark-
ably, while some of the later events persist at steady-state, many
new transcriptional events appear that involve the regulation of
the cell cycle, DNA replication and oxidative phosphorylation.
The observation that genes involved in DNA replication and cell
cycle regulation are actively transcribed at 48 hours is compatible
with the entry of Myc activated P493 cells into S-phase by 48
hours [14].
Not only does ANRO reveal waves of transcriptional events
associated with specific cellular functions following Myc induction,
but the use of GSMA also allows the reconstruction of putative
transcription factors that might be involved in regulating these
waves of transcriptional events. Specifically, by clustering groups of
genes that are enriched in their promoters for specific transcription
factor motifs as a function of time after Myc induction, we could re-
construct the putative transcriptional networks. The very early
transcriptional events mimic those observed after serum stimulation
of fibroblasts. A large middle wave of genes (1–6 hr) appears to be
regulated by different transcription factors, most notable being
Myc/Max, E2F and NFkB. This wave of genes is involved in
ribosomal biogenesis, nucleotide metabolism and energy regulation.
At a late, steady-state phase, a distinct transcriptionally active group
Table 1. Selected results for statistically significant changes in gene expression from either Array-based NRO or total RNA as
measured on the Illumina microarray platform.
Symbol Gene Name
Total RNA
(fold change)
NRO
(fold change)
known
Myc target
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 13.69 13.09 Y
NME1 non-metastatic cells 1 7.05 10.83 Y
DSCR2 Down syndrome critical region gene 2 7.31 6.69 Y
PAICS phosphoribosylaminoimidazole carboxylase 6.42 6.54 Y
EXOSC5 exosome component 5 5.23 6.29 Y
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 6.45 6.15 Y
GEMIN5 gem (nuclear organelle) associated protein 5 4.11 5.66
SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ system) 10.84 5.45
PPAT phosphoribosyl pyrophosphate amidotransferase 7.32 5.37 Y
IMPDH2 IMP (inosine monophosphate) dehydrogenase 2 5.32 4.99 Y
MCM4 MCM4 minichromosome maintenance deficient 4 4.56 4.70 Y
ACAT1 acetyl-Coenzyme A acetyltransferase 1 4.06 3.85 Y
GEMIN4 gem (nuclear organelle) associated protein 4 3.26 3.54 Y
NME2 non-metastatic cells 2 2.78 3.49
APRT adenine phosphoribosyltransferase 1.90 3.24 Y
CDK4 cyclin-dependent kinase 4 3.22 3.16 Y
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 1.77 2.55 Y
DDX1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 2.11 2.53 Y
MINA MYC induced nuclear antigen 2.83 2.52 Y
NME4 non-metastatic cells 4 2.55 2.46 Y
ACLY ATP citrate lyase 1.96 1.99
CEBPB CCAAT/enhancer binding protein 1.62 1.98 Y
BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog 1.58 1.57 Y
Fold changes are calculated between cells treated with tetracycline for 48 hrs versus untreated cells. Known MYC targets are as indicated (Y=yes).
doi:10.1371/journal.pone.0009691.t001
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motifs for ARNT (HIF), USF (which has the same core consensus
site as Myc) and YY1 are also represented in the promoters of these
genes.Thesetranscription factorsareassociated with genesinvolved
in DNA replication and cell cycle regulation.
In addition to the ability to re-construct transcriptional events
globally following Myc activation, ANRO also permits the
identification of direct Myc target genes which could now be
defined more precisely. ANRO adds the transactome or the
missing component of evidence for transcriptional regulation
through the direct measurement of nuclear run-on. The
transactome completes the tripartite components, which include
demonstration of physical binding of a transcription factor to its
target genes by chromatin immunoprecipitation (ChIP-chip or
ChIP-PET) and mRNA level changes (as determined by standard
gene expression profiling with microarrays). Coupling these three
components of measuring transcriptional regulation, we identified
in the human P493-6 B cell model, a set of direct Myc targets that
are involved in ribosomal biogenesis, nucleotide metabolism,
energy metabolism and cell cycle progression. GSEA reveals a
stem cell signature amongst the direct Myc up-regulated genes,
suggesting the Myc maintains these cells in an undifferentiated
stem cell-like state. These observations taken together further
support the notion that Myc is a master transcription factor that
participates in the regulation of genes in essentially all phases of
the cell cycle to stimulate cell growth and proliferation.
Our studies also underscore the fact that Myc requires other
transcription factors to regulate subsets of genes involved in
specific cellular functions in different phases of the cell cycle. Early
after Myc induction, genes involved in signaling and transcription
are abundantly transcribed. Myc regulates subsequent events that
induce genes involved in ribosomal biogenesis among other
biosynthetic processes. In this regard, it is notable that ribosomal
biogenesis has been proposed to be a primordial function of Myc
during evolution [5]. While cells prepare for biosynthesis in the
earlier cell cycle phases, genes involved in the regulation of cell
proliferation persists at the late, steady-state phase with Myc and
E2F playing a major role. In addition to new lessons learned about
the Myc transcriptional network through the use of ANRO, we
provide here a new experimental approach that should provide a
better understanding of any transcriptional network downstream
of known transcription factors. The application of ANRO to the
study of oncogenic or stem cell transcription factors should rapidly
enrich our knowledge of these important transcriptional networks.
Figure 4. Heatmap of a time course of gene regulation in human P493-6 B cells following Myc gene induction. At each time point, 6
independent experiments were performed, except for the 48 hr time point that has 10 experiments shown. Coordinate increase in gene expression
for 970 genes is contrasted between nascent nuclear gene transcription (NRO RNA) and changes in gene expression at the whole cell level (Total
RNA) at the timepoints indicated. Changes in gene expression are calculated as logratios relative to 0time. Inset shows all changes measured (10,530).
doi:10.1371/journal.pone.0009691.g004
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Nuclei Isolation for In Vitro labeling of Nascent RNA
Collect 20610
6 cells by spinning 3–5 min at ,2166g; Wash
once with Cold PBS and spin again at the same speed; Carefully
decant PBS, add 10 ml Cell Lysis Buffer (20 mM Tris-HCl, pH
7.5, 5 mM MgCl2, 20 mM NaCl, 100 mM Sucrose, 0.25% NP-
40) to cell pellet; Sit on ice for ,5 min with hand-mixing several
times in between; Spin at ,2166g, carefully decant and drain off
supernatant; Add100 ml Nuclei Storage Buffer (50.0 mM Tris-
HCl, pH 8.0, 5.0 mM MgCl2, 0.1 mM EDTA, 45% Glycerol) to
resuspend each nuclear pellet.
Labeling of Nascent RNA (In Vitro NRO Reaction
To above 100 ml nuclei, add 100 ml2 6NRO Reaction Buffer
(300 mM KCl, 10 mM MgCl2, 2 mM of cold rATP, rCTP, rGTP
and 1 mM Biotin-modified UTP, ribonuclease inhibitor such as
Invitrogen RNaseOUT
TM 100 Units); Incubate at 28uC for 25–
30 min with constant mixing; (Optional: add cold rUTP to a final
1 mM, continue the incubation for another 5–10 min;) Add
RNase-free DNase I (such as 100 Units of Roche DNase I),
incubate 10 min at 37uC; Add 15 ml 3:1 of Proteinase K (20 mg/
ml) : 10% SDS; incubate 10 min at 37uC.
Purification of Total Nuclear RNA
Variousprotocols canbe used, here is a modified QiagenRNeasy
RNA Isolation Kit procedure. Add RLT Buffer (supplemented with
2-BME) and bring the volume up to ,650 ml; Add 750 ml 100%
Ethanol; Mix well and load onto RNeasy Column; Spin at Max
Speed and discard flow through; Wash ONCE with 700 ml RW1
Buffer; Wash TWICE with Kit Wash Solution; After last wash, spin
additional 2 min at Max Speed to remove trace wash solution;
Transfer column to collection tubes, add 50–100 ml RNase-free
H2O (prewarmed at 60uC) at the column center, let sit at room
temperature for ,2 min; Spin 2 min at Max speed to elute RNA;
Quantify RNA amount.
Preparation of Avidin-beads
Using magnet stand, sequentially wash DynabeadsH M-280
Streptavidin (30 ml per sample) with equal volume of 16PBS,
RNase-free Solution A (100 mM NaOH, 50 mM NaCl), RNase-
free Solution B (100 mM NaCl), twice of each wash; Wash once
with DynalH kilobaseBINDER
TM Binding Solution (supplemented
with ribonuclease inhibitor such as Invitrogen RNaseOUT
TM 100
Units per sample); Resuspend beads in equal volume of DynalH
kilobaseBINDER
TM Binding Solution (30 ml per sample, supple-
mented with ribonuclease inhibitor as above), put on ice.
Figure 5. Pathway enrichment analysis of changes in gene expression sorted by their first appearance as upregulated in the NRO
RNA. Identical analyses were run for both NRO and total RNA as indicated. Examples of time-dependent up-regulated pathways at early, middle, and
late time points.
doi:10.1371/journal.pone.0009691.g005
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Aliquot equal volume of total nuclear RNA (typically 5–10 mgi n
30 ml of RNase-free H2O), denatured ,3 min at 68uC and
immediately put on ice; Add carefully into corresponding Beads
tubes prepared above; Gently pipette up and down, rotate 3 hrs at
,6 rpm at room temperature or ,2 hrs at room temperature,
then 4uC over night. Using magnet stand, sequentially wash RNA-
bound DynabeadsH sequentially with RNase-free H2O six times
(twice 600 ml, twice 400 ml, and twice 200 ml).
1
st and 2
nd Strand cDNA Synthesis
Various sources of reagents can be used, here is a modified
procedure using Ambion TotalPrep RNA Amplification Kit.
Resuspend above washed RNA-bound beads in 24 ml T7N6
Primer Solution (22 ml RNase-free H2O + 2 ml of 10 pmoles/ml
T7N6); Denature bound RNA at 68uC 3 min with shaking; Rotate
at room temperature 10 min for T7(N)6 annealing; Add 16 mlo f
1
st Strand Mix (4 ml1 0 61
st Strand Buffer, 8 ml dNTPs, 2 ml
RNase Inhibitor, 2 ml ArrayScript); Incubate at 25, 28, 32, 37uC
1 min each, then 42uC 2 hrs (with constant mixing). To the above
40 ml1
st strand reaction on beads, add RNase H Mix (10 ml
RNase-free H2O, 6 ml of 10X 2
nd Strand Buffer, 2 ml of Invitrogen
Random Primers at 3 mg/ml stock solution, 2 ml RNase H);
Incubate 30 min at 37uC with rotation; 68uC 3 min to separate 1
st
Strand cDNA completely from beads; Quick spin and immediately
put on magnet; Transfer supernatants into new tubes; Let stand
5 min at room temperature for random primer annealing. To the
above 60 ml RNase H Reaction, add 2
nd Strand Synthesis Mix
(30 ml RNase-free H2O, 4 mlo f1 0 62
nd Strand Buffer, 4 ml
dNTPs, 2 ml DNA Polymerase); Incubate 2 hrs at 37uC.
cDNA Purification, cRNA Synthesis and cRNA Purification
Various sources of reagents can be used, here is a modified
procedure using Ambion TotalPrep RNA Amplification Kit. Add
250 ml cDNA Binding Buffer to each sample, mix well and load
onto cDNA Filter Cartridge; Spin 1 min at 10,0006g, discard flow-
through;Washoncewith 500 mlWashBuffer,spinadditional 2 min
to remove residue solution and transfer cartridge to cDNA Elution
Tube; Elute cDNA with 20 mlo fH 2O (55uC preheated). Add IVT
(in vitro transcription) Mix (T7 10X6Reaction Buffer, T7 Enzyme
Mix, Biotin-NTP Mix, 2.5 ml each), incubate 14 hrs at 37uC. Add
350 ml cRNA Binding Buffer and 250 ml of 100% Ethanol, mix well
and load onto cRNA Filter Cartridge; Spin ,1 min at 10,0006g,
discard flow-through; Wash once with 500 ml Wash Buffer, spin
additional 2 min to remove residue solution and transfer cartridge
to cRNA Elution Tube; Elute cRNA with 100 mlo fH 2O.
Figure 6. GSMA geneset analysis of coordinate changes in gene expression based on the presence of transcription factor binding
sites in selected gene lists. Enrichment values are sorted by their first appearance as upregulated in the NRO RNA. Identical analyses were run for
both NRO and total RNA as indicated. Inset highlights genesets up-regulated at 48 hr.
doi:10.1371/journal.pone.0009691.g006
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Human Jurkat E6-1 T cells and B Lymphoma P493-6 cells were
cultured in RPMI-1640 Medium (GIBCO-BRL, Gaithersburg,
MD) supplemented with 10% heat-inactivated FCS (Hyclone,
Logan, UT) and antibiotics, and incubated in a humidified
incubator (95% air and 5% CO2)a t3 7 uC. Jurkat cells were
stimulated with 40 ng/ml phorbol 12-myristate 13-acetate (PMA)
and 1 mM ionomycin (Sigma, St. Louis, MO) (P+I). To induce the
expression of Myc in P493 cells, cells were first cultured in 0.1 mg/
ml tetracycline (tet) for 48 hr; then withdrew tet by changing new
medium and cells were collected at 15 min, 30 min, 1 hr, 3 hr,
6 hr, and 48 hr following tet withdrawal.
Array analysis
For Affymetrix Exon arrays, 10 mg nuclear run-on cRNA was
converted to cDNA and labeled using the Affymetrix Whole
Transcript (WT) Sense Target Labeling Assay (cat. no. 900670)
according to the manufacturer’s recommendations. Total RNA was
labeled in a similar fashion using an input of 100 ng RNA without
ribosomal RNA reduction. 5.5 ug of fragmented, labeled sense target
DNA generated from either NRO or Total cRNA was hybridized
to Affymetrix GeneChip Human Exon 1.0 ST Arrays using the
Affymetrix FS450_0001 fluidics station protocol and quantitated
using an Affymetrix 3000 7G scanner. Data was processed through
Affymetrix GeneChip Operating Software (GCOS) Expression
Console and further analyzed (for differential gene expression and
alternative splicing) using software from JMP (JMP Genomics 3.0)
andExonandGeneArrayExpressionAnalysisfromBiotique-XRAY
(Reno, NV). For Illumina arrays, biotin-labeled cRNA (750 ng total
RNA-cRNA or 2 mg NRO-cRNA) was combined with hybridization
buffer + formamide and hybridized (16 hr) at 55uC to Illumina’s
Sentrix HumanRef-8 Expression BeadChips (Illumina, San Diego,
CA,Cat#11201828). After hybridization, the hybridization cartridge
was disassembled and the beadchip slide array was placed in a 55uC
high temperature wash followed by washing and blocking at room
temperature. Bound biotinylated cRNA was stained with streptavi-
din-Cy3 and further washed. The dry beadchip was stored in a dark
box until scanned. The beadchip slide was quantitated using
Illumina’s BeadStation 500GX Genetic Analysis Systems scanner.
Preliminary analysis of the scanned data including monitoring of
quality control metrics was performed using the Illumina BeadStudio
software.
Quantitative RT-PCR (QRT-PCR) Analysis
Reverse transcription was performed using either total RNA
isolated from cells or cDNA and cRNA from NRO RNA (specific
primer design: GAPDH, C-GTA AGGAGATGCTGCATTCG-
CC, 3-GCAACAATATCCACTTTACCAGAGTT, E-CCCTGA-
CAACTCTTTTCATCTTCTAG , 5-GGTCTACATGGCAACT-
GTGAGGAG ,4-TGGGATTTCCATTGATGACAAGC, CD69,
B-GCTCCAGCAAAGACTTTCACTGTAGC,2-ATAGAGAG-
ATTACCAGTATATCTTGTATAACTACT, E-ACATGGTGC-
TACTCTTGCTGTCAT, 5-CTACATCTGAAATAGGTACA-
ATGTTTG, D-AGTTCCTGTCCTGTGTGCTGTAATG) pro-
cessed with Applied Biosystems (Foster City, CA) High-Capacity
cDNA Archive kit first-strand synthesis system for RT-PCR
according to the manufacturer’s protocol. QRT-PCR amplifica-
tions were carried out in duplicate or triplicate on an ABI PrismH
7300 Sequence Detection System, using SybrGreen incorporation
for detection. Relative gene expressions are calculated by using the
2
2DDCT method. The normalized DCt value of each sample is
calculated using GAPDH as an endogenous control gene. Fold
changevaluesarepresentedasaveragefoldchange=2
2(average DDCt)
for genes in treated relative to control samples.
Array Data Analysis
For Affymetrix Exon arrays, data was normalized by the RMA
method [23] For Illumina arrays preliminary analysis of the scanned
data was performed using Illumina BeadStudio software as described
[24]. Any gene consistently below a background threshold level of
D=.98 for all samples was eliminated from further analysis. Z-
transformation for normalization was performed on each Illumina
sample/array on a stand-alone basis[25]. Significant changes ingene
expression for both Affymetrix and Illumina data were calculated by
Z test [25]. Significant genelists were calculated by selecting genes
which satisfied a significance threshold criteria of Z test p-values less
than or equal to 0.001 (10
23), a false discovery rate less than or equal
to 0.1, and either a fold change 61 . 5o rg r e a t e r ,o raZr a t i ov a l u e s
g r e a t e ro rl e s st h a n63.0. For direct comparison of results between
Affymetrix and Illumina array data sets (logratios) were joined on the
basis of HUGO gene names after averaging of duplicate genes.
Hierarchical clustering was performed using the Cluster and
TreeView software programs, developed at Stanford University
[26].The clustering algorithmwas settocomplete linkage clustering
using the uncentered Pearson correlation.
GSMA Gene Set analysis and Functional Annotation
Gene Set Matrix Analysis (GSMA) [24] was performed using the
median differences for differentially expressed genes tested against
genesets derived from a varietyof sources (forexample, the Pathway
genelists were originally obtained from the Gene Set Enrichment
Analysis (GSEA) website maintained by the Broad Institute @
(www.broad.mit.edu/gsea). PAGE calculations [27] were automat-
ically calculated according to the formula: Z=(Sm2m)*m
1/2/s
where Sm is the median of the logratio values of genes for a given
gene set and the size of the given gene set is m. The median of total
logratio values (m) and standard deviation of total logratio values (s)
of a given microarray data set were calculated for all genes between
two experimental groups. Functional annotation was performed
using the Database for Annotation, Visualization and Integrated
Discovery (DAVID), NIAID/NIH [19].
Supporting Information
Figure S1 ANRO transcripts are both full length and concordant
with total RNA. Results from Affymetrix exon arrays illustrate
congruent patterns of gene expression for the MYC regulated Protein
Kinase, DNA-activated, catalytic polypeptide (PRKDC) gene in either
(a) Array based-NRO or, (b) total RNA, at both the individual exon
and the whole gene level. The PRKDC gene is encoded by a total of
91 exons and spans approximately 190 Kb on chromosome 22q.
Found at: doi:10.1371/journal.pone.0009691.s001 (0.38 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0009691.s002 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0009691.s003 (0.18 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0009691.s004 (0.17 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0009691.s005 (0.40 MB
DOC)
Table S5
Found at: doi:10.1371/journal.pone.0009691.s006 (0.04 MB
DOC)
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